维持性血液透析合并高尿酸血症患者的临床治疗研究进展(4)
[18]Tsuruta Y，Kikuchi K，Tsuruta Y，et al.Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia：a randomized controlled study[J].Hemodial Int，2015，19(4)：514-520.
[19]Yilmaz MI，Saglam M，Caglar K，et al.The determinants of endothelial dysfunction in CKD：oxidative stress and asymmetric dimethylarginine[J].Am J Kidney Dis，2006，47(1)：42-50.
[20]Mitsuboshi S，Yamada H，Nagai K，et al.Comparison of clinical advantage between Topiroxostat and Febuxostat in hem-odialysis patients[J].Biol Pharm Bull，2017，40(9)：1463-1467.
[21]Wu XW，Lee CC，Muzny DM，et al.Urate oxidase：primary structure and evolutionary implications[J].Proc Natl Acad Sci USA，1989，86(23)：9412-9416.
[22]刘丽秋，赵震霄，赵秀珍.氯沙坦治疗尿毒症血液透析病人高血壓的临床研究[J].青岛大学医学院学报，2001，37(4)：20.
[23]Zinman B，Wanner C，Lachin JM，et al.Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J].N Engl J Med，2015，373(22)：2117-2128.
[24]Neal B，Perkovic V，Mahaffey KW，et al.Canagliflozin and cardiovascular and renal events in type 2diabetes[J].N Engl J Med，2017，377(7)：644-657.
[25]Mahaffey KW，Neal B，Perkovic V，et al.Canagliflozin for primary and secondary prevention of cardiovascular events：results from the CANVAS program (Canagliflozin cardiovascular assessment study)[J].Circulation，2018，137(4)：323-334.
(收稿日期：2018-08-29 本文编辑：祁海文), http://www.100md.com(彭婷 刘玲)
[19]Yilmaz MI，Saglam M，Caglar K，et al.The determinants of endothelial dysfunction in CKD：oxidative stress and asymmetric dimethylarginine[J].Am J Kidney Dis，2006，47(1)：42-50.
[20]Mitsuboshi S，Yamada H，Nagai K，et al.Comparison of clinical advantage between Topiroxostat and Febuxostat in hem-odialysis patients[J].Biol Pharm Bull，2017，40(9)：1463-1467.
[21]Wu XW，Lee CC，Muzny DM，et al.Urate oxidase：primary structure and evolutionary implications[J].Proc Natl Acad Sci USA，1989，86(23)：9412-9416.
[22]刘丽秋，赵震霄，赵秀珍.氯沙坦治疗尿毒症血液透析病人高血壓的临床研究[J].青岛大学医学院学报，2001，37(4)：20.
[23]Zinman B，Wanner C，Lachin JM，et al.Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J].N Engl J Med，2015，373(22)：2117-2128.
[24]Neal B，Perkovic V，Mahaffey KW，et al.Canagliflozin and cardiovascular and renal events in type 2diabetes[J].N Engl J Med，2017，377(7)：644-657.
[25]Mahaffey KW，Neal B，Perkovic V，et al.Canagliflozin for primary and secondary prevention of cardiovascular events：results from the CANVAS program (Canagliflozin cardiovascular assessment study)[J].Circulation，2018，137(4)：323-334.
(收稿日期：2018-08-29 本文编辑：祁海文), http://www.100md.com(彭婷 刘玲)